NDC 80425-0292-01 - Cyclobenzaprine HCL ER
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 80425-0292
- Requested NDC
- 80425-0292-01
- Package NDCs from labels
- 80425-0292-1, 80425-0292-2, 80425-0292-3, 80425-0292-01
- Manufacturer
- Advanced Rx Pharmacy of Tennessee, LLC
- Effective date
- 2024-12-31
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Cyclobenzaprine HCL ER - Advanced Rx Pharmacy of Tennessee, LLC | Advanced Rx Pharmacy of Tennessee, LLC | 2024-12-31 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 80425-0292-1 | Cyclobenzaprine HCLER | 30 in 1 BOTTLE | CAPSULE, EXTENDED RELEASE | 30 | 2 | |
| 80425-0292-2 | Cyclobenzaprine HCLER | 60 in 1 BOTTLE | CAPSULE, EXTENDED RELEASE | 60 | 2 | |
| 80425-0292-3 | Cyclobenzaprine HCLER | 90 in 1 BOTTLE | CAPSULE, EXTENDED RELEASE | 90 | 2 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 80425-0292 | CYCLOBENZAPRINE HCL ER (CYCLOBENZAPRINE HCL) CAPSULE, EXTENDED RELEASE [ADVANCED RX PHARMACY OF TENNESSEE, LLC] | 2 | Current NDC, 3 package rows | 20250102_f8360da5-f1d3-1d89-e053-6294a90ad31c.zip |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 80425-0292-1 | EA - Each | 80425-0292 | 2e44b7d0-6868-4599-90e1-24ed3e9d2e0d | 1 | 2023-06-06 |
| 80425-0292-2 | EA - Each | 80425-0292 | b9d25f7c-b567-4941-b32c-9b6c1772fcda | 1 | 2023-06-06 |
| 80425-0292-3 | EA - Each | 80425-0292 | 6480d838-8c92-4e23-8982-918a017f2b7c | 1 | 2023-06-06 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| CYCLOBENZAPRINE HYDROCHLORIDE | CYCLOBENZAPRINE HYDROCHLORIDE | NuCare Pharmaceuticals,Inc. | 8bdc725e-22e3-0f32-e053-2a95a90ae8a9 | 2024-06-14 | Warnings, Adverse reactions | 0VE05JYS2P |
| Cyclobenzaprine hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | NCS HealthCare of KY, LLC dba Vangard Labs | e332763b-00c6-41bf-84ae-a07d9ef79697 | 2024-06-11 | Warnings, Adverse reactions | 0VE05JYS2P |
| Cyclobenzaprine Hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | Teva Pharmaceuticals USA, Inc. | ca74d27a-f7c6-462d-a913-1cfa061bd8f3 | 2024-05-31 | Warnings, Adverse reactions | NDA021777 828358 828353 0VE05JYS2P |
| CYCLOBENZAPRINE HYDROCHLORIDE | CYCLOBENZAPRINE HYDROCHLORIDE | A-S Medication Solutions | d64ca498-81c6-4e10-ba82-3a50ee47bcfc | 2024-05-29 | Warnings, Adverse reactions | 0VE05JYS2P |
| Cyclobenzaprine Hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | Asclemed USA, Inc. | 07e3ec53-f1f2-4231-aec6-1772a146ba88 | 2024-05-07 | Warnings, Adverse reactions | 0VE05JYS2P |
| AMRIX | CYCLOBENZAPRINE HYDROCHLORIDE | Cephalon, LLC | 3902123b-1365-ac3c-0934-afff9eeeb1bd | 2024-04-30 | Warnings, Adverse reactions | NDA021777 828358 828353 0VE05JYS2P |
| CYCLOBENZAPRINE HYDROCHLORIDE | CYCLOBENZAPRINE HYDROCHLORIDE | NuCare Pharmaceuticals,Inc. | 00dbe051-a392-e2c6-e063-6394a90ab7f3 | 2024-03-27 | Warnings, Adverse reactions | 0VE05JYS2P |
| CYCLOBENZAPRINE HYDROCHLORIDE | CYCLOBENZAPRINE HYDROCHLORIDE | NuCare Pharmaceuticals,Inc. | 0f8ba2c0-38e7-a536-e063-6294a90ace8d | 2024-03-26 | Warnings, Adverse reactions | 0VE05JYS2P |
| Cyclobenzaprine hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | NuCare Pharmaceuticals,Inc. | c68d17e2-2311-8e17-e053-2995a90a565b | 2024-03-11 | Warnings, Adverse reactions | 0VE05JYS2P |
| Cyclobenzaprine Hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | Medsource Pharmaceuticals | 12645f19-fffc-8b08-e063-6394a90a5c55 | 2024-02-27 | Warnings, Adverse reactions | 0VE05JYS2P |
| Cyclobenzaprine Hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | Bryant Ranch Prepack | 90c7a982-6442-4241-a60b-b5dfab2abb71 | 2024-01-31 | Warnings, Adverse reactions | 0VE05JYS2P |
| Cyclobenzaprine Hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | Bryant Ranch Prepack | c86303a0-7c8b-415e-acac-1070b7d0d445 | 2024-01-15 | Warnings, Adverse reactions | 0VE05JYS2P |
| CYCLOBENZAPRINE HYDROCHLORIDE | CYCLOBENZAPRINE HYDROCHLORIDE | Proficient Rx LP | 34ff8a08-0177-451f-9dbc-e21582346196 | 2024-01-01 | Warnings, Adverse reactions | 0VE05JYS2P |
| CYCLOBENZAPRINE HYDROCHLORIDE | CYCLOBENZAPRINE HYDROCHLORIDE | Amneal Pharmaceuticals of New York LLC | 31bb92f6-ec8c-4636-8b07-8814417fe78e | 2023-12-31 | Warnings, Adverse reactions | 0VE05JYS2P |
| Cyclobenzaprine hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | Bryant Ranch Prepack | 4a2d3cae-5c64-4986-9707-cc213b70b7ad | 2023-10-19 | Warnings, Adverse reactions | 0VE05JYS2P |
| Cyclobenzaprine Hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | Asclemed USA, Inc. | 74af1727-e84f-4dad-82be-045e7d23beaf | 2023-09-06 | Warnings, Adverse reactions | 0VE05JYS2P |
| CYCLOBENZAPRINE HYDROCHLORIDE | CYCLOBENZAPRINE HYDROCHLORIDE | Proficient Rx LP | 88bdee56-d6d9-4f14-be77-1e6898ba36f5 | 2023-09-01 | Warnings, Adverse reactions | 0VE05JYS2P |
| Cyclobenzaprine hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | Bryant Ranch Prepack | 6ebaccfc-f57c-4547-ade0-6a6e204f5ea0 | 2023-03-27 | Warnings, Adverse reactions | 0VE05JYS2P |
| Cyclobenzaprine Hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | Asclemed USA, Inc. | 68db3c3b-8da1-4852-90b0-3172f842aa02 | 2023-03-02 | Warnings, Adverse reactions | 0VE05JYS2P |
| CYCLOBENZAPRINE HYDROCHLORIDE | CYCLOBENZAPRINE HYDROCHLORIDE | A-S Medication Solutions | b524d150-0a83-42d1-a884-b930e49760cd | 2023-02-06 | Warnings, Adverse reactions | 0VE05JYS2P |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.